V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210030912 | 210021520 | 1.54 | 82 | Curative (C) | 2017-07-29 | 2017-10-08 | FLAIR Trial | N | N | 210031313 | FLAIR TRIAL |
| 210030913 | 210021523 | null | null | null | 2018-06-19 | 2018-06-30 | BENDAMUSTINE + RITUXIMAB | N | N | 210031354 | BENDAMUSTINE + RITUXIMAB |
| 210030914 | 210011798 | null | 94 | Disease modification (D) | null | 2015-02-09 | FLAIR Trial | N | N | 210031381 | FLAIR TRIAL |
| 210030915 | 210011814 | 1.83 | 76 | Adjuvant (A) | 2017-08-30 | 2017-08-30 | VINCRISTINE | N | N | 210031465 | VINCRISTINE |
| 210030917 | 210011824 | 1.8 | 103.6 | Disease modification (D) | 2016-03-22 | 2017-12-26 | BENDAMUSTINE + RITUXIMAB | N | N | 210031507 | BENDAMUSTINE + RITUXIMAB |
| 210030918 | 210027520 | 1.72 | 83 | Disease modification (D) | 2015-02-06 | 2015-10-07 | Vincristine (weekly) | N | N | 210031512 | VINCRISTINE |
| 210030919 | 210011832 | 1.59 | null | Palliative (P) | null | 2018-01-30 | FLAIR Trial | 02 | N | 210031516 | FLAIR TRIAL |
| 210030920 | 210011839 | 1.79 | 62.9 | null | 2014-02-01 | 2014-03-17 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 210031542 | FCR |
| 210030921 | 210011840 | 1.6 | 86.8 | Disease modification (D) | 2016-11-25 | 2016-11-28 | FCR Oral - Cycle 2 onwards | 02 | N | 210031543 | FCR |
| 210030922 | 210011845 | null | 78 | Palliative (P) | 2016-07-31 | 2016-09-27 | Vincristine (weekly) | 02 | N | 210031570 | VINCRISTINE |
| 210030923 | 210011857 | 1.79 | 109.8 | Adjuvant (A) | 2017-10-15 | 2017-10-21 | FCR | N | N | 210031647 | FCR |
| 210030924 | 210011861 | 1.63 | 89.6 | Disease modification (D) | 2017-08-09 | 2017-08-09 | VINCRISTINE | 01 | null | 210031677 | VINCRISTINE |
| 210030925 | 210011864 | 1.57 | 72.4 | Disease modification (D) | 2013-08-22 | 2014-01-01 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | null | N | 210031682 | FCR |
| 210030927 | 210011873 | 1.8 | null | null | 2015-12-22 | 2015-12-22 | BENDAMUSTINE + RITUXIMAB | null | N | 210031749 | BENDAMUSTINE + RITUXIMAB |
| 210030928 | 210011885 | null | null | null | 2014-07-07 | 2014-07-07 | Bendamustine+Rituximab(Sub Courses) | N | N | 210031805 | BENDAMUSTINE + RITUXIMAB |
| 210030929 | 210011889 | 1.8 | null | Curative (C) | 2014-09-16 | 2014-12-04 | FLAIR Trial | Y | N | 210031811 | FLAIR TRIAL |
| 210030930 | 210011895 | 1.73 | 82.6 | Palliative (P) | 2013-10-25 | 2013-12-30 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 210031827 | FCR |
| 210030931 | 210011899 | 1.57 | 68.7 | Curative (C) | 2015-01-22 | 2015-11-02 | FCR Oral - Cycle 2 onwards | Y | N | 210031850 | FCR |
| 210030932 | 210011899 | 1.6 | 65.2 | Curative (C) | 2017-10-14 | 2017-11-21 | BENDAMUSTINE + RITUXIMAB | 02 | N | 210031850 | BENDAMUSTINE + RITUXIMAB |
| 210030933 | 210011904 | 1.59 | 64 | Palliative (P) | null | 2016-06-13 | FCR Oral - Cycle 2 onwards | N | N | 210031879 | FCR |
| 210030934 | 210011912 | 1.65 | null | null | 2013-02-25 | 2013-05-17 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | null | null | 210031944 | FCR |
| 210030935 | 210011915 | 1.55 | 69.6 | Curative (C) | 2017-02-25 | 2017-09-10 | FCR Oral - Cycle 2 onwards | N | N | 210031959 | FCR |
| 210030936 | 210011919 | null | 44 | Palliative (P) | 2016-06-30 | 2016-09-14 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | Y | N | 210032019 | FCR |
| 210030937 | 210011925 | null | 96 | Disease modification (D) | null | 2013-12-18 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 210032021 | FCR |
| 210030938 | 210021596 | 1.57 | 54 | Palliative (P) | 2013-11-24 | 2014-07-18 | FCR Oral - Cycle 2 onwards | N | N | 210032022 | FCR |
| 210030939 | 210011936 | 1.71 | 91.4 | Palliative (P) | 2015-11-24 | 2016-01-28 | BENDAMUSTINE + RITUXIMAB | N | N | 210032066 | BENDAMUSTINE + RITUXIMAB |
| 210030940 | 210011955 | 1.78 | 66.6 | Disease modification (D) | 2016-02-06 | 2016-02-06 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | null | N | 210032274 | FCR |
| 210030941 | 210011959 | 1.8 | 137.6 | Palliative (P) | 2014-06-15 | 2014-08-12 | FCR Oral - Cycle 2 onwards | N | N | 210032287 | FCR |
| 210030942 | 210011961 | 1.7 | 100.2 | Palliative (P) | 2016-02-13 | 2016-04-14 | FLAIR Trial | N | N | 210032293 | FLAIR TRIAL |
| 210030943 | 210011962 | 1.72 | 72.7 | Palliative (P) | 2014-08-16 | 2014-09-20 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 2 | N | 210032310 | FCR |
| 210030944 | 210011972 | null | 78 | Disease modification (D) | 2017-03-12 | 2017-03-19 | BENDAMUSTINE + RITUXIMAB | N | null | 210032412 | BENDAMUSTINE + RITUXIMAB |
| 210030945 | 210021621 | 1.76 | 144 | Curative (C) | 2017-07-08 | 2017-07-08 | Bendamustine+Rituximab(Sub Courses) | N | N | 210032422 | BENDAMUSTINE + RITUXIMAB |
| 210030946 | 210011985 | null | 103.6 | Curative (C) | 2013-08-15 | 2013-09-16 | Vincristine (weekly) | N | N | 210032491 | VINCRISTINE |
| 210030947 | 210011986 | null | null | Curative (C) | 2017-06-06 | 2017-06-21 | FCR | N | N | 210032497 | FCR |
| 210030948 | 210011988 | 1.64 | null | Curative (C) | 2014-12-22 | 2014-12-22 | BENDAMUSTINE + RITUXIMAB | 02 | N | 210032500 | BENDAMUSTINE + RITUXIMAB |
| 210030949 | 210021628 | 1.73 | 104 | Curative (C) | 2013-07-01 | 2014-04-30 | FCR Oral - Cycle 1 | N | N | 210032509 | FCR |
| 210030950 | 210011994 | 1.84 | null | Curative (C) | 2016-08-20 | 2016-11-02 | Vincristine (weekly) | N | null | 210032534 | VINCRISTINE |
| 210030951 | 210035051 | 1.75 | 108 | Disease modification (D) | null | 2016-09-06 | Bendamustine+Rituximab(Sub Courses) | N | N | 210032535 | BENDAMUSTINE + RITUXIMAB |
| 210030952 | 210011998 | 1.84 | 90 | Curative (C) | 2014-09-11 | 2014-09-12 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 210032549 | FCR |
| 210030954 | 210012000 | 1.8 | 112.8 | Palliative (P) | 2018-03-30 | 2018-07-14 | FLAIR Trial | null | N | 210032559 | FLAIR TRIAL |
| 210030955 | 210027585 | 1.47 | 78.6 | Disease modification (D) | 2017-10-24 | 2017-11-27 | BENDAMUSTINE + RITUXIMAB | null | N | 210032573 | BENDAMUSTINE + RITUXIMAB |
| 210030956 | 210036132 | 1.78 | 77.9 | Curative (C) | 2015-02-13 | 2015-05-06 | FLAIR Trial | N | N | 210032574 | FLAIR TRIAL |
| 210030957 | 210012005 | 1.84 | 24.7 | Palliative (P) | 2017-10-29 | 2017-12-07 | Vincristine (weekly) | 02 | N | 210032587 | VINCRISTINE |
| 210030958 | 210012008 | 1.72 | 134.2 | Curative (C) | 2016-12-13 | 2017-02-23 | Bendamustine+Rituximab(Sub Courses) | N | N | 210032608 | BENDAMUSTINE + RITUXIMAB |
| 210030959 | 210031225 | 1.54 | 42 | Palliative (P) | 2013-02-12 | 2013-05-12 | FCR Oral - Cycle 2 onwards | null | null | 210032625 | FCR |
| 210030960 | 210021641 | null | 10.5 | Disease modification (D) | null | 2016-07-05 | BENDAMUSTINE + RITUXIMAB | N | N | 210032638 | BENDAMUSTINE + RITUXIMAB |
| 210030961 | 210012019 | null | null | Neo-adjuvant (N) | 2012-10-29 | 2014-10-27 | FLAIR Trial | 01 | N | 210032683 | FLAIR TRIAL |
| 210030962 | 210012031 | 1.54 | 33.5 | Adjuvant (A) | 2013-07-10 | 2013-09-19 | FCR Oral - Cycle 2 onwards | 02 | N | 210032731 | FCR |
| 210030963 | 210021653 | 1.59 | 102 | Disease modification (D) | 2018-10-28 | 2018-12-08 | Vincristine (weekly) | 01 | N | 210032734 | VINCRISTINE |
| 210030964 | 210012036 | null | 93.5 | Curative (C) | 2019-01-28 | 2019-02-05 | FCR Oral - Cycle 2 onwards | null | N | 210032743 | FCR |